<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="58676"><DrugName>fenofibrate + simvastatin (oral, hyperlipidemia), Abbott</DrugName><DrugNamesKey><Name id="43012493">Cholib</Name><Name id="42875476">Zolip</Name></DrugNamesKey><DrugSynonyms><Name><Value>fenofibrate + simvastatin (oral, hyperlipidemia), Solvay</Value></Name><Name><Value>fenofibrate + simvastatin</Value></Name><Name><Value>Zolip</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>SLV-285</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>fenofibrate + simvastatin (oral, hyperlipidemia), Abbott</Value></Name><Name><Value>Cholib</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>fenofibrate + simvastatin (oral, hyperlipidemia), Abbott/ Green Cross</Value></Name><Name><Value>fenofibrate + simvastatin (oral, hyperlipidemia), Abbott/GC Pharma</Value></Name><Name><Value>49562-28-9</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>79902-63-9</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20199">Solvay SA</CompanyOriginator><CompaniesPrimary><Company id="16583">GC Pharma</Company><Company id="13601">Abbott Laboratories</Company></CompaniesPrimary><CompaniesSecondary><Company id="20199">Solvay SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="58676" type="Drug"><TargetEntity id="644223" type="siDrug">Fenofibrate/simvastatin</TargetEntity></SourceEntity><SourceEntity id="13601" type="Company"><TargetEntity id="4295903265" type="organizationId">Abbott Laboratories</TargetEntity></SourceEntity><SourceEntity id="16583" type="Company"><TargetEntity id="4295881833" type="organizationId">Green Cross Corp</TargetEntity></SourceEntity><SourceEntity id="20199" type="Company"><TargetEntity id="4298448939" type="organizationId">Solvay SA (Paris Branch)</TargetEntity></SourceEntity><SourceEntity id="175" type="ciIndication"><TargetEntity id="10062060" type="MEDDRA"></TargetEntity><TargetEntity id="D006949" type="MeSH"></TargetEntity><TargetEntity id="-1908196798" type="omicsDisease"></TargetEntity><TargetEntity id="971" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="584" type="ciIndication"><TargetEntity id="10061227" type="MEDDRA"></TargetEntity><TargetEntity id="D052439" type="MeSH"></TargetEntity><TargetEntity id="-386237446" type="omicsDisease"></TargetEntity><TargetEntity id="2898" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="205" type="Action"><TargetEntity id="437" type="Mechanism">HMG-CoA Reductase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="72" type="Action"><TargetEntity id="1052" type="Mechanism">Lipid Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="PTGT-00943" type="ciTarget"><TargetEntity id="112452388431563" type="siTarget">3-hydroxy-3-methylglutaryl-coenzyme A reductase</TargetEntity><TargetEntity id="2750" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Hyperlipidemia - Bulgaria - May-2014</FirstLaunched><FirstLaunched>Hyperlipidemia - Croatia - May-2014</FirstLaunched><FirstLaunched>Hyperlipidemia - Slovenia - May-2014</FirstLaunched><FirstLaunched>Lipid metabolism disorder - Bulgaria - May-2014</FirstLaunched><FirstLaunched>Lipid metabolism disorder - Croatia - May-2014</FirstLaunched><FirstLaunched>Lipid metabolism disorder - Slovenia - May-2014</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="175">Hyperlipidemia</Indication><Indication id="584">Lipid metabolism disorder</Indication></IndicationsPrimary><ActionsPrimary><Action id="205">HMG CoA reductase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1389">Lipid metabolism modulator</Action><Action id="72">Antihyperlipidemic agent</Action></ActionsSecondary><Technologies><Technology id="175">Drug combination</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C10</Code><Name>HYPOLIPIDAEMICS/ANTI-ATHEROMA PREPARATIONS</Name></Ephmra><Ephmra><Code>C10A1</Code><Name>Statins (HMG-CoA reductase inhibitors)</Name></Ephmra></EphmraCodes><LastModificationDate>2018-08-21T11:44:41.000Z</LastModificationDate><ChangeDateLast>2018-08-21T00:00:00.000Z</ChangeDateLast><AddedDate>2007-11-12T16:15:04.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="13601" linkType="Company"&gt;Abbott Laboratories&lt;/ulink&gt;, following its acquisition of &lt;ulink linkID="20199" linkType="Company"&gt;Solvay&lt;/ulink&gt;'s pharmaceutical business [&lt;ulink linkID="1075358" linkType="Reference"&gt;1075358&lt;/ulink&gt;], using technology licensed from &lt;ulink linkID="1047474" linkType="Company"&gt;Elan Drug Technologies&lt;/ulink&gt; [&lt;ulink linkID="996581" linkType="Reference"&gt;996581&lt;/ulink&gt;], has developed and launched SLV-285 (Zolip; Cholib), an oral  fixed-dose combination of &lt;ulink linkID="16986" linkType="Drug"&gt;fenofibrate&lt;/ulink&gt; and &lt;ulink linkID="44313" linkType="Drug"&gt;simvastatin&lt;/ulink&gt;,  for the treatment of   hyperlipidemia and mixed dyslipidemia   [&lt;ulink linkID="850151" linkType="Reference"&gt;850151&lt;/ulink&gt;], [&lt;ulink linkID="850152" linkType="Reference"&gt;850152&lt;/ulink&gt;], [&lt;ulink linkID="1091322" linkType="Reference"&gt;1091322&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2013, approval was granted in the EU for Cholib (fenofibrate 145 mg + simvastatin 20 or 40 mg) tablets as adjunctive therapy to diet and exercise in high cardiovascular risk adult patients with mixed dyslipidemia to reduce triglycerides and increase HDL cholesterol levels when LDL cholesterol levels are adequately controlled with the corresponding dose of simvastatin 20 and 40 mg monotherapy [&lt;ulink linkID="1484556" linkType="Reference"&gt;1484556&lt;/ulink&gt;]. In May 2014, the drug was launched in Croatia, Slovenia and Bulgaria [&lt;ulink linkID="1602107" linkType="Reference"&gt;1602107&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase III trials were ongoing in March 2010 [&lt;ulink linkID="1091322" linkType="Reference"&gt;1091322&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In addition to the original fenofibrate product (Tricor), Abbott in collaboration with Solvay (and predecessor companies) has also developed and launched a delayed-release fenofibrate product (&lt;ulink linkID="55355" linkType="Drug"&gt;TriLipix&lt;/ulink&gt;).&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;By March 2012, it was presumed a filing had been submitted in Europe [&lt;ulink linkID="1268238" linkType="Reference"&gt;1268238&lt;/ulink&gt;]. In June 2013, the CHMP of the EMA adopted a positive opinion for SLV-285 (fenofibrate 145 mg + simvastatin 20 or 40 mg) tablets as adjunctive therapy to diet and exercise in high cardiovascular risk adult patients with mixed dyslipidemia to reduce triglycerides and increase HDL cholesterol levels when LDL cholesterol levels are adequately controlled with the corresponding dose of simvastatin 20 and 40 mg monotherapy [&lt;ulink linkID="1445864" linkType="Reference"&gt;1445864&lt;/ulink&gt;]. In August 2013, the product (Cholib) was approved in the EU [&lt;ulink linkID="1484556" linkType="Reference"&gt;1484556&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In November 2014, the combination was approved as Cholib in Korea [&lt;ulink linkID="1639131" linkType="Reference"&gt;1639131&lt;/ulink&gt;]. In February 2015, the combination was launched with partner &lt;ulink linkID="16583" linkType="Company"&gt;GC Pharma&lt;/ulink&gt; (formerly Green Cross Corp) [&lt;ulink linkID="1645303" linkType="Reference"&gt;1645303&lt;/ulink&gt;], [&lt;ulink linkID="1994206" linkType="Reference"&gt;1994206&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In June 2012, a randomized, parallel-assignment, double-blind, 12-week phase III trial (&lt;ulink linkID="90602" linkType="Protocol"&gt;NCT01674712&lt;/ulink&gt;; M13-377, 2011-005924-16) was initiated in Argentina, Germany, Czech Republic, Mexico, Poland, Romania and  Russia, in dyslipidemic patients (expected n = 600) with high risk of cardiovascular disease,  to evaluate the safety and efficacy of SLV-285 (fenofibrate 145 mg + simvastatin 20 or 40 mg) versus matching monotherapies.  The trial was expected to be completed by September 2013. In March 2013, the trial was  ongoing. In October 2013, the trial was completed  [&lt;ulink linkID="1449253" linkType="Reference"&gt;1449253&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2006, a multicenter, phase III, double-blind, randomized study (&lt;ulink linkID="5467" linkType="Protocol"&gt;NCT00362934&lt;/ulink&gt;; C-LF0242780-01-0503) was initiated in Europe, to evaluate the safety and efficacy of SLV-285 (fenofibrate 145 mg + simvastatin 20 or 40 mg) versus atorvastatin (10 mg) monotherapy, in patients (n = 516) with mixed hyperlipidemia/dyslipidemia at risk of cardiovascular disease, and not adequately controlled by atorvastatin (10 mg). The primary endpoints included 12-week change in LDL-C, TG and HDL-C. The study was completed in August 2008 [&lt;ulink linkID="1177256" linkType="Reference"&gt;1177256&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2006, a multicenter, phase III, double-blind, randomized study (&lt;ulink linkID="5466" linkType="Protocol"&gt;NCT00362206&lt;/ulink&gt;; C-LF0242780-01-0504) was initiated in Europe and South Africa, to evaluate the safety and efficacy of SLV-285 (fenofibrate 145 mg + simvastatin 20 or 40 mg) versus pravastatin (40 mg) monotherapy, in patients (n = 423) with mixed hyperlipidemia/dyslipidemia at risk of cardiovascular disease, and not adequately controlled by pravastatin (40 mg). The primary endpoints included 12-week change in LDL-C, TG and HDL-C. The study was completed in September 2008 [&lt;ulink linkID="1177250" linkType="Reference"&gt;1177250&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2006, a randomized, double-blind, active-controlled,  phase III trial (&lt;ulink linkID="4667" linkType="Protocol"&gt;NCT00352183&lt;/ulink&gt;; C-LF0242780-01-0502) was initiated in Europe, Australia and New Zealand, to evaluate the safety and efficacy of SLV-285 (fenofibrate 145 mg + simvastatin 40 mg) versus simvastatin (40 mg) monotherapy, in patients (n = 450) with mixed hyperlipidemia/dyslipidemia at risk of cardiovascular disease, and not adequately controlled by simvastatin (40 mg). The primary outcome was the change in LDL-C, TG and HDL-C. The study was completed in August 2008 [&lt;ulink linkID="850359" linkType="Reference"&gt;850359&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2005,  a randomized, double-blind, active-controlled, parallel-group, phase III trial (&lt;ulink linkID="5465" linkType="Protocol"&gt;NCT00349375&lt;/ulink&gt;; C-LF0242780-01-0501) was initiated in Europe, to evaluate the safety and efficacy of SLV-285 (fenofibrate 145 mg + simvastatin 20 mg) versus simvastatin (20 mg) monotherapy, in patients (n = 1040) with mixed hyperlipidemia/dyslipidemia at risk of cardiovascular disease, and not adequately controlled by simvastatin (20 mg). The primary outcome was the change in LDL-C, TG and HDL-C. The study was completed in September 2008 [&lt;ulink linkID="850358" linkType="Reference"&gt;850358&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous studies&lt;/subtitle&gt;In October 2003, a randomized, double-blind, factorial-assignment, phase III trial (&lt;ulink linkID="162432" linkType="Protocol"&gt;NCT00542178&lt;/ulink&gt;; 509, N01 HC095178-19) was initiated in the US and Canada, to assess the effects of the ACCORD treatments on the progression of the diabetic retinopathy in patients (expected n = 3472) participating in the ACCORD study. The trial was expected to be completed by December 2009. By November 2013, the trial had been completed [&lt;ulink linkID="1509196" linkType="Reference"&gt;1509196&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 1999, the &lt;ulink linkID="1003240" linkType="Company"&gt;National Heart Lung and Blood Institute&lt;/ulink&gt; commenced a phase III, open-label, randomized, active-controlled study (&lt;ulink linkID="7639" linkType="Protocol"&gt;NCT00000620&lt;/ulink&gt;; ACCORD) in North America, to evaluate the safety and efficacy of preventing major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults (n = 10251) with type 2 diabetes using intensive glycemic control, intensive blood pressure control, and multiple lipid therapy (including fenofibrate + simvastatin). By December 2009, enrollment in the study had been completed [&lt;ulink linkID="1177270" linkType="Reference"&gt;1177270&lt;/ulink&gt;]. In March 2010, data from 5518 patients  receiving open-label simvastatin plus fenofibrate or placebo, were reported. The annual rate of first occurrence of non-fatal myocardial infarction, non-fatal stroke or death from cardiovascular causes of 2.2% in the fenofibrate arm and 2.4% in the placebo group which was not significant. However, cardiovascular risk was reduced by 31% in patients with atherogenic dyslipidemia. A further study, REALIST, was to be conducted worldwide to quantify the results [&lt;ulink linkID="1082671" linkType="Reference"&gt;1082671&lt;/ulink&gt;], [&lt;ulink linkID="1082741" linkType="Reference"&gt;1082741&lt;/ulink&gt;]. In June 2010, further data from this trial were presented at the 78th European Atherosclerosis Society Congress in Hamburg, Germany [&lt;ulink linkID="1113675" linkType="Reference"&gt;1113675&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2005, data  from  trials  of fenofibrate plus simvastatin combination in   more than 800 patients were available. In the trials, conducted by &lt;ulink linkID="18077" linkType="Company"&gt;Merck &amp;amp; Co&lt;/ulink&gt;, fenofibrate plus &lt;ulink linkID="44313" linkType="Drug"&gt;simvastatin&lt;/ulink&gt; was significantly  more effective in reducing lipid levels than statin alone [&lt;ulink linkID="628188" linkType="Reference"&gt;628188&lt;/ulink&gt;], [&lt;ulink linkID="850628" linkType="Reference"&gt;850628&lt;/ulink&gt;], [&lt;ulink linkID="850612" linkType="Reference"&gt;850612&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Abbott Laboratories holds exclusive worldwide rights, following its acquisition of Solvay Pharmaceuticals in February 2010 [&lt;ulink linkID="1075358" linkType="Reference"&gt;1075358&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2008, Solvay had entered into an agreement to use sustained-release technology from Elan Drug Technologies for the development of SLV-285 [&lt;ulink linkID="996581" linkType="Reference"&gt;996581&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="SI">Slovenia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2014-05-31T00:00:00.000Z</StatusDate><Source id="1602107" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2015-02-01T00:00:00.000Z</StatusDate><Source id="1645303" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2015-02-01T00:00:00.000Z</StatusDate><Source id="1645303" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="SI">Slovenia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2014-05-31T00:00:00.000Z</StatusDate><Source id="1602107" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="BG">Bulgaria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2014-05-31T00:00:00.000Z</StatusDate><Source id="1602107" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16583">GC Pharma</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2015-02-01T00:00:00.000Z</StatusDate><Source id="1645303" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="HR">Croatia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2014-05-31T00:00:00.000Z</StatusDate><Source id="1602107" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16583">GC Pharma</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2015-02-01T00:00:00.000Z</StatusDate><Source id="1645303" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="HR">Croatia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2014-05-31T00:00:00.000Z</StatusDate><Source id="1602107" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="BG">Bulgaria</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2014-05-31T00:00:00.000Z</StatusDate><Source id="1602107" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2013-08-26T00:00:00.000Z</StatusDate><Source id="1484556" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2013-08-26T00:00:00.000Z</StatusDate><Source id="1484556" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2011-08-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2011-08-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2015-04-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2011-08-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2015-04-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2011-08-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2015-04-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2011-08-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2011-08-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2010-02-15T00:00:00.000Z</StatusDate><Source id="1075358" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2010-02-15T00:00:00.000Z</StatusDate><Source id="1075358" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2012-03-02T00:00:00.000Z</StatusDate><Source id="1268238" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2012-03-02T00:00:00.000Z</StatusDate><Source id="1268238" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2014-11-11T00:00:00.000Z</StatusDate><Source id="1639131" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2014-11-11T00:00:00.000Z</StatusDate><Source id="1639131" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2010-02-15T00:00:00.000Z</StatusDate><Source id="1075358" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2010-02-15T00:00:00.000Z</StatusDate><Source id="1075358" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2010-02-15T00:00:00.000Z</StatusDate><Source id="1075358" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2010-02-15T00:00:00.000Z</StatusDate><Source id="1075358" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2010-02-15T00:00:00.000Z</StatusDate><Source id="1075358" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2010-02-15T00:00:00.000Z</StatusDate><Source id="1075358" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2012-06-30T00:00:00.000Z</StatusDate><Source id="1449253" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2012-06-30T00:00:00.000Z</StatusDate><Source id="1449253" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2012-06-30T00:00:00.000Z</StatusDate><Source id="1449253" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20199">Solvay SA</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2005-10-04T00:00:00.000Z</StatusDate><Source id="628188" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20199">Solvay SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2005-11-30T00:00:00.000Z</StatusDate><Source id="850358" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20199">Solvay SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2006-01-31T00:00:00.000Z</StatusDate><Source id="850359" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20199">Solvay SA</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2006-01-31T00:00:00.000Z</StatusDate><Source id="850359" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20199">Solvay SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2006-01-31T00:00:00.000Z</StatusDate><Source id="850359" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20199">Solvay SA</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2006-01-31T00:00:00.000Z</StatusDate><Source id="850359" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20199">Solvay SA</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2006-09-30T00:00:00.000Z</StatusDate><Source id="1177250" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20199">Solvay SA</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2006-09-30T00:00:00.000Z</StatusDate><Source id="1177250" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00943"><Name>HMG CoA reductase</Name><SwissprotNumbers><Swissprot>O08424</Swissprot><Swissprot>O24594</Swissprot><Swissprot>O26662</Swissprot><Swissprot>O28538</Swissprot><Swissprot>O51628</Swissprot><Swissprot>O59469</Swissprot><Swissprot>O64966</Swissprot><Swissprot>O64967</Swissprot><Swissprot>O74164</Swissprot><Swissprot>O76819</Swissprot><Swissprot>P00347</Swissprot><Swissprot>P04035</Swissprot><Swissprot>P09610</Swissprot><Swissprot>P12683</Swissprot><Swissprot>P12684</Swissprot><Swissprot>P13702</Swissprot><Swissprot>P14773</Swissprot><Swissprot>P14891</Swissprot><Swissprot>P16237</Swissprot><Swissprot>P16393</Swissprot><Swissprot>P20715</Swissprot><Swissprot>P29057</Swissprot><Swissprot>P29058</Swissprot><Swissprot>P34135</Swissprot><Swissprot>P34136</Swissprot><Swissprot>P43256</Swissprot><Swissprot>P48020</Swissprot><Swissprot>P48021</Swissprot><Swissprot>P48022</Swissprot><Swissprot>P51639</Swissprot><Swissprot>P54960</Swissprot><Swissprot>Q00583</Swissprot><Swissprot>Q01237</Swissprot><Swissprot>Q01559</Swissprot><Swissprot>Q03163</Swissprot><Swissprot>Q0DY59</Swissprot><Swissprot>Q10283</Swissprot><Swissprot>Q12577</Swissprot><Swissprot>Q12649</Swissprot><Swissprot>Q29512</Swissprot><Swissprot>Q41437</Swissprot><Swissprot>Q41438</Swissprot><Swissprot>Q58116</Swissprot><Swissprot>Q59468</Swissprot><Swissprot>Q5R6N3</Swissprot><Swissprot>Q9V1R3</Swissprot><Swissprot>Q9XEL8</Swissprot><Swissprot>Q9XHL5</Swissprot><Swissprot>Q9Y7D2</Swissprot><Swissprot>Q9YAS4</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="13601">Abbott Laboratories</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14005">Alkermes plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="16583">GC Pharma</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20199">Solvay SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(cc2)Cl</Smiles><Smiles>CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C</Smiles><Smiles>CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C.CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(cc2)Cl</Smiles></StructureSmiles><Deals><Deal id="119888" title="Korea Green Cross to market Fournier's micronized fenofibrate franchise in Korea"/><Deal id="127002" title="Solvay to use sustained release technology from Elan Drug Technologies for the development of Zolip"/></Deals><hasSWOTs>N</hasSWOTs></drugRecordOutput>